重组体人α-2b干扰素联合乙型肝炎疫苗、左旋咪唑涂布剂治疗慢性乙型肝炎

Clinical Study on Hepatitis B Vaccine and Liniment Lenamisole Combined with Anfuron in the Treatment of Chronic Hepatitis B

目的:探讨重组体人α-2b干扰素联合乙型肝炎疫苗、左旋咪唑涂布剂治疗慢性乙型肝炎的临床疗效。方法:176例慢性乙型肝炎患者随机分为两组:A组和B组,每组88例。A组采用大剂量重组体人α-2b干扰素和左旋咪唑涂布剂、乙型肝炎疫苗联合治疗;B组采用重组体人α-2b干扰素治疗。两组疗程均为24周。结果:A组的食欲不振、腹胀改善均明显优于B组(P均<0.01);A组治疗结束时、治疗后6个月ALT正常率、HBeAg阴转率及HBV DNA阴转率均明显优于B组(P均<0.05)。结论:重组体人α-2b干扰素和左旋咪唑涂布剂、乙型肝炎疫苗联合治疗慢性乙型肝炎,其疗效持久,效果良好,值得临床应用。

Objective：To evaluate the mechanism and clinical effect of Anfuron （Recombinant Human Interferon α-2b Injection） combined with hepatitis B vaccine and liniment levamisole for treα- ting chronic hepatitis B （CHB）. Methods： One hundred and seventy six CHB patients were randomly divided into group A and group B. which were treated with large-dose of Recombinant Human Interferon α-2b combined with hepatitis B vaccine and liniment levamisole, and with the same dose of Recombinant Human Interferon α-2b alone. Respectively, for 24 weeks, and followed up for 6 months. Results： By the end of treatment, the rate for ALT recovering to normal level was higher and the rates for HbeAg, HBV-DNA to change to be negative in group A were superior to that in group B. Followed up for 6 months, the rate for ALT recovering to normal and the rates for HbeAg,HBV-DNA to change to be negative in group A were superior to that in group B. Conclusion： The combined treatment with Recombinant Human Interferon α-2b,liniment levamisole and hepatitis B vaccine for CHB could shorten the duration of the use of Recombinant Human Interferon α-2b, with lasting and good effect.